IDEAYA Biosciences

Recent news

• Rating change
  Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
  Market Newswire · 2026/6/12
• Rating change
  LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
  Market Newswire · 2026/7/27
• Rating change
  A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60
  Market Newswire · 2026/8/5
• Rating change
  Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63
  Market Newswire · 2026/7/7
• Rating change
  Goldman Sachs Maintains IDEAYA Biosciences(IDYA.US) With Hold Rating, Raises Target Price to $36
  Market Newswire · 2026/6/4
• Rating change
  Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (CVKD) and IDEAYA Biosciences (IDYA)
  TipRanks · 2026/6/16
• Rating change
  RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $48
  Market Newswire · 2026/7/7
• Rating change
  UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
  Market Newswire · 2026/6/9
• Rating change
  Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $54
  Market Newswire · 2026/6/2
• Rating change
  J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62
  Market Newswire · 2026/8/11
• LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
  Market Newswire · 2026/9/28
• Rating change
  Citizens JMP Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $42
  Market Newswire · 2026/8/7
• Rating change
  Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $60
  Market Newswire · 2026/8/6
• Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $57
  Market Newswire · 2026/9/9
• Rating change
  Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59
  Market Newswire · 2026/8/5
• Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
  Market Newswire · 2026/9/1
• Rating change
  Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
  Market Newswire · 2026/9/1
• Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
  Market Newswire · 2026/9/11
• Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $60
  Market Newswire · 2026/8/20
• Rating change
  RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48
  Market Newswire · 2026/8/6

Headlines are aggregated automatically and are not independently verified or edited by our team.